
Ethyl cyclohexanecarboxylate | CAS:3289-28-9
Ethyl cyclohexanecarboxylate
- 名称:环己甲酸乙酯 | Ethyl cyclohexanecarboxylate
- CAS号:3289-28-9
- 别名:Cyclohexanecarboxylic acid ethyl ester
- 分子式:C9H16O2
- 分子量:156.22
- EINESC号:221-945-7
产品描述
物理化学性质
没有数据 | 没有数据 |
---|
安全数据
没有数据 | 没有数据 |
---|
产品合成路线
名称 | CAS号 |
---|
更多
文章
同行评议文献
Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.Yohei Kosugi et al.Xenobiotica; the fate of foreign compounds in biological systems, 45(4), 345-352 (2014-11-12)
Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha.Tsai-Shin Chiang et al.PloS one, 9(4), e94885-e94885 (2014-04-16)
Interactions of endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells.Camille C Savary et al.Drug metabolism and disposition: the biological fate of chemicals, 42(8), 1235-1240 (2014-05-17)
Occurrence and measurement of nifedipine and its nitropyridine derivatives in human blood plasma.J Dokladalova et al.Journal of chromatography, 231(2), 451-458 (1982-09-10)
The first pass metabolism of nifedipine in man.D G Waller et al.British journal of clinical pharmacology, 18(6), 951-954 (1984-12-01)
Structure-function analysis of porcine cytochrome P450 3A29 in the hydroxylation of T-2 toxin as revealed by docking and mutagenesis studies.Guyue Cheng et al.PloS one, 9(9), e106769-e106769 (2014-09-04)
Isotopic sensitivity in the microsomal oxidation of the dihydropyridine calcium entry blocker nifedipine.J L Born et al.Chemical research in toxicology, 2(1), 57-59 (1989-01-01)
Da-Chaihu-Tang alters the pharmacokinetics of nifedipine in rats and a treatment regimen to avoid this.Ju-Xiu He et al.The Journal of pharmacy and pharmacology, 66(11), 1623-1630 (2014-06-26)
Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.Yoshihiko Shimokawa et al.Biological & pharmaceutical bulletin, 37(11), 1727-1735 (2014-11-05)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|

相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!